Evidence map›Paper›PMID 32674954›Full record

ArticleUrologic oncology2020

Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration.

Ericka M Sohlberg, I-Chun Thomas, Jaden Yang, Kristopher Kapphahn, Timothy J Daskivich, Ted A Skolarus, Jeremy B Shelton, Danil V Makarov, Jonathan Bergman, Christine Ko Bang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ericka M SohlbergDepartment of Urology, Stanford University School of Medicine, Stanford, CA.
I-Chun ThomasVeterans Affairs Palo Alto Health Care System, Palo Alto, CA.
Jaden YangQuantitative Sciences Unit, Stanford University, Stanford, CA.
Kristopher KapphahnQuantitative Sciences Unit, Stanford University, Stanford, CA.
Timothy J DaskivichDivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA.
Ted A SkolarusDepartment of Urology, University of Michigan, VA Ann Arbor Healthcare System, Center for Clinical Management and Research, Ann Arbor, MI.
Jeremy B SheltonDepartment of Urology, UCLA; West Los Angeles VA Medical Center, LA County Department of Health Services, Los Angeles, CA.
Danil V MakarovDepartments of Urology and Population Health, New York University Langone Medical Center, Veterans Affairs New York Harbor Healthcare System, New York, NY.
Jonathan BergmanDepartment of Urology, UCLA; West Los Angeles VA Medical Center, LA County Department of Health Services, Los Angeles, CA.
Christine Ko BangDepartment of Radiation Oncology, VA Maryland Health Care System, Baltimore, MD.
Mary K GoldsteinVeterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Todd H WagnerDepartment of Surgery, Stanford University School of Medicine, Stanford, CA; VA Center for Innovation to Implementation, Palo Alto, CA.
James D BrooksDepartment of Urology, Stanford University School of Medicine, Stanford, CA.
Manisha DesaiQuantitative Sciences Unit, Stanford University, Stanford, CA; Department of Medicine, Stanford University School of Medicine, Stanford, CA.
John T LeppertDepartment of Urology, Stanford University School of Medicine, Stanford, CA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Medicine, Stanford University School of Medicine, Stanford, CA; VA Center for Innovation to Implementation, Palo Alto, CA. Electronic address: jleppert@stanford.edu.

Funding

De-implementation of low value castration for men with prostate cancerR37CA222885 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAINI, SAMEER DEV, SKOLARUS, TED ALBERT · 2018 to 2023
$3.6M
A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary MalignancyK08CA230155 · NCI · CEDARS-SINAI MEDICAL CENTER · PI DASKIVICH, TIMOTHY · 2018 to 2022
$909k
Personalized Life Expectancy to Encourage High Value Prostate Cancer CareI01HX002126 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI LEPPERT, JOHN THOMAS · 2018 to 2021
–
HSRD VA I01 HX002126NCI NIH HHS K08 CA230155NCI NIH HHS R37 CA222885
6 · The paper itself

Abstract

purposeAccurate life expectancy estimates are required to inform prostate cancer treatment decisions. However, few models are specific to the population served or easily implemented in a clinical setting. We sought to create life expectancy estimates specific to Veterans diagnosed with prostate cancer. MATERIALS AND

methodsUsing national Veterans Health Administration electronic health records, we identified Veterans diagnosed with prostate cancer between 2000 and 2015. We abstracted demographics, comorbidities, oncologic staging, and treatment information. We fit Cox Proportional Hazards models to determine the impact of age, comorbidity, cancer risk, and race on survival. We stratified life expectancy estimates by age, comorbidity and cancer stage.

resultsOur analytic cohort included 145,678 patients. Survival modeling demonstrated the importance of age and comorbidity across all cancer risk categories. Life expectancy estimates generated from age and comorbidity data were predictive of overall survival (C-index 0.676, 95% CI 0.674-0.679) and visualized using Kaplan-Meier plots and heatmaps stratified by age and comorbidity. Separate life expectancy estimates were generated for patients with localized or advanced disease. These life expectancy estimates calibrate well across prostate cancer risk categories.

conclusionsLife expectancy estimates are essential to providing patient-centered prostate cancer care. We developed accessible life expectancy estimation tools for Veterans diagnosed with prostate cancer that can be used in routine clinical practice to inform medical-decision making.

Indexed as

Life ExpectancyAgedCohort StudiesHumansMaleMiddle AgedModels, StatisticalProstatic NeoplasmsSurvival RateUnited StatesUnited States Department of Veterans AffairsVeterans HealthComorbidityLife expectancyProstatic neoplasmsVeterans Health

Identifiers

PMID32674954
PMCPMC7438257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.